secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0001193125-24-286169
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B
--------------------------------------------------------------------------------

- Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.
- Hengrui Pharma eligible for $75M upfront, up to $200M development/regulatory milestones, plus commercial milestones and mid-single to low-double digit royalties.
- In 11 evaluable SCLC patients at therapeutic doses, 8 partial responses observed (~73% ORR, including unconfirmed) with manageable safety profile.
- IDEAYA targets US IND filing for SHR-4849 in H1 2025; cash runway guided to at least 2028 unchanged.
- SHR-4849 offers rational combination opportunity with IDEAYA's Phase 1 PARG inhibitor IDE161 for enhanced preclinical efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/0001193125-24-286169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/d917390d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-286169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer